Melena Clinical Trial
— FIRMOfficial title:
Magnetically Controlled Capsule Endoscopy First vs. Standard Algorithm in Patients With Melena (FIRM Trial): a Multicenter, Randomized Controlled Trial
Verified date | September 2020 |
Source | Changhai Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
MCE first algorithm is not inferior to standard of care algorithm in terms of further bleeding in hemodynamically stable patients with acute overt and non-hematochezia GI bleeding.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 1, 2022 |
Est. primary completion date | September 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age = 18 years - Presenting to the outpatient department or emergency department with melena (without hematemesis) within the previous 48 hours - Hemodynamically stable (blood pressure > 100/60 mmHg and heart rate < 100 bpm) at presentation - No endoscopy performed after the new onset of melena Exclusion Criteria: - Presenting with hematochezia and/or hematemesis within the previous 48 hours of presentation - Hemodynamically stable after initial volume resuscitation - Drop of hemoglobin level = 2 g/dL/day, and/or need of transfusion = 2 units of packed red blood cells per day - Contraindications of CE (e.g. dysphagia, Zenker's diverticulum, esophageal stricture, known or suspected gastric or small bowel obstruction or perforation, gastroparesis, history of upper gastrointestinal surgery or abdominal surgery altering gastrointestinal anatomy, or post-abdominal radiation, etc.) - Presence of internal cardiac defibrillator (ICD), pacemaker and/or other implanted electronic devices (cochlea, drug infusion pump, nerve stimulator, etc.) or magnetic metal foreign bodies; possibility of requiring an MRI examination prior to capsule excretion - Patients who cannot undergo surgery in the event of capsule retention - Pregnant and/or lactating women - Patients with altered mental status (such as hepatic encephalopathy) - Patients moribund from terminal malignant diseases or other end-stage illnesses with a limited life expectancy - Unable to consent |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Changhai Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The rate of bleeding lesions detection. | Detection rate of bleeding lesions is defined as proportion of patients in whom a potential bleeding lesion is identified. Visualization of gross blood (fresh/coffee grounds) without any lesion will not be considered as a positive diagnosis. The panel will provide a diagnosis based upon the lesion presenting the highest potential for bleeding if there are many lesions detected. | 1 month | |
Secondary | The time of the bleeding lesions detected from admission | 1 month | ||
Secondary | The number of procedures patients underwent for detection of the bleeding lesions | 1 month | ||
Secondary | The number of colonoscopy needed | 1 month | ||
Secondary | Rate of therapeutic intervention required of all patients | Therapeutic interventions include therapeutic endoscopy, radiologic intervention or surgery. | 1 month | |
Secondary | The length of hospital stay | 1 month | ||
Secondary | The cumulative direct cost of hospitalization | 1 month | ||
Secondary | Time to therapeutic intervention from presentation | 1 month | ||
Secondary | The rate of recurrent bleeding within 30 days of discharge | Further bleeding is defined as overt (hematemesis, melena or hematochezia) or occult (anemia or fecal occult blood positive) bleeding requiring subsequent hospitalization or transfusion, and/or signs of hypovolemic shock (systolic blood pressure of <100 mmHg and pulse rate >100 per min) or a drop-in hemoglobin level of >2g/dL per 24hours. | 1 month | |
Secondary | The all-cause mortality within 30 days of discharge | 1 month | ||
Secondary | Transfusion rate | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00389935 -
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
|
Phase 2 | |
Completed |
NCT00534677 -
The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
|
Phase 4 | |
Active, not recruiting |
NCT01863303 -
Epidemiological Study of Colorectal Cancer in WuHan
|
N/A | |
Completed |
NCT03028064 -
Point of Care Testing of Platelet Function in Patients With Acute Upper Gastrointestinal Bleeding
|
||
Completed |
NCT03955055 -
Study of Early Endocapsule (EC) in Clinical Decision Unit Versus Standard of Care Work-up for GI Bleeding
|
N/A | |
Completed |
NCT02442830 -
Comparing Early Capsule Deployment to Current Standard of Care for Management of Gastrointestinal Bleeding
|
N/A | |
Not yet recruiting |
NCT01371591 -
Capsule Endoscopy for Hemorrhage in the Emergency Room
|
N/A |